Eli Lilly reports results from Covid-19 phase 2 antibody drug trial

Eli Lilly announced on Wednesday it had found proof of concept data from an interim analysis of the BLAZE-1 clinical trial that showed a reduced rate of hospitalization for coronavirus patients treated with its neutralizing antibody drug. CNBC's Meg Tirrell reports.